Professional Documents
Culture Documents
8.5 Infusion of Hypertonic Mannitol Solutions: Fluid Physiology
8.5 Infusion of Hypertonic Mannitol Solutions: Fluid Physiology
Previous | Index
The hypertonicity causes passive movement of water across lipid barriers in response to the osmotic gradient.
Mannitol is a monosaccharide which is easy to produce and stable in solution. It is used clinically in doses ranging
from 0.25 to 1.5 g/kg body weight. Solutions of 10% and 20% mannitol are readily clinically available.
Cerebral effects
Mannitol does not cross the blood brain barrier so an elevated plasma osmolality due to a infusion of hypertonic
mannitol is effective in removing fluid from the brain. This is called 'mannitol osmotherapy'. In the past other
hypertonic solutions (eg hypertonic urea solution) have been used and currently in some places hypertonic glycerol
solutions are available as an alternative to mannitol.
Mannitol infusions are useful to acutely decrease elevated intracranial pressure due to an intracranial space
occupying lesion. A typical use would be in a patient with an intracerebral haematoma due to an acute traumatic head
injury. The effect is rapid in onset (minutes) but only temporary (as the mannitol is excreted) but its use buys time
for urgent definitive therapy (eg surgical evacuation of the haematoma and surgical haemostasis). A typical dose in
an adult would be 0.5-1.5g/kg administered as the 20% solution.
Repeated doses of mannitol have less effect and as some slowly enters the brain, rebound intracranial hypertension
is a risk. As the blood-brain barrier is probably disrupted in damaged areas of the brain, mannitol may be both less
effective here and also more may enter the brain at these places. However, the therapeutic effect of mannitol is not
dependent on a specific action at damaged areas of the brain but rather on a global effect in decreasing intracranial
fluid volume and intracranial pressure so this has little relevance for a first dose of mannitol and especially if
definitive surgical treatment is successful. Much more problematical is use of repeated doses of mannitol in IC U
patients with traumatic intracranial hypertension in whom there is no surgically correctable cause; such use is usually
futile.
The brain cells also compensate for the presence of continued hypertonicity by the intracellular production of
'idiogenic osmoles'. The effect is to increase intracellular tonicity and allow brain cell volume to return towards
normal presumably with improvement of intracellular functions despite the continued hypertonicity.
Use of mannitol infusions is common intraoperatively in some neurosurgical procedures. The aim is to decrease
intracranial pressure and produce a 'slack brain' to facilitate surgical access.
Mannitol does not cross cell membranes so the cell volume of most other cells in the body is also decreased.
Renal effects
In the renal glomeruli, mannitol is freely filtered. It is not secreted or reabsorbed by the tubules. In the doses used
clinically it retains water with it in the tubule and causes an 'osmotic diuresis'. C onsequently, mannitol is classified as
an 'osmotic diuretic'. The high flow of retained tubule fluid tends to have a flushing effect and washes fluid and solutes
from the kidney. This effect is useful clinically in management of rhabdomyolysis. The aim is to 'wash' the myoglobin
out of the tubules and prevent it precipitating there with obstruction and development of acute renal failure. The
effect of mannitol for this use is aided by maintenance of adequate intravascular volume and by urinary alkalinisation
(by administration of IV sodium bicarbonate).
Other effects
The increased intravascular water volume decreases the red cell concentration (decreased haematocrit) with a
resultant decrease in blood viscosity. This may improve flow and oxygen delivery to some areas.
Mannitol has free radical scavenging properties and these may contribute to its therapeutic effects (though this has
not so far been established).
Effects of Mannitol
Intracellular dehydration
Expansion of EC F volume (except brain EC F)
Haemodilution
Diuresis due osmotic effects and EC F expansion
Non-Osmotic Effects